Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: nord who wrote (5462)	10/5/1998 10:10:00 PM
From: John Metcalf	Respond to of 6136

Nord, I was going to claim the title (dufus), but I see I am too late -:) Rick's point is not what the money did for Chiron, though CHIR shareholders did get $10 per share special dividend (a sign that management did not have better plans for the money). If 49% of Agouron were sold for even a 75% premium to market, which is too low given their independence, Peter Johnson and crew would have $1B to invest above their already substantial R&D.

To: nord who wrote (5462)	10/5/1998 11:08:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 6136

>> my point is that i also heard about an offer from dupont with the early data on sustiva and the announced intention for dupont to get into m&a to improve pharm. pipe. maybe i am missing something but who posted the idea on thread first doen't give anyone the right to be disrespectful [dufus] of others << nord: I did not and will not bestow the title "dufus" on any given individual. I therefore claim privileged "dufus calling" status as a result of my contributions to the thread. Nonetheless, I apologize for the tone. Cheers! Rick